Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of BEA 2180 BR in COPD
NCT02242279Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2004
- Primary completion
- Dec 2004
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of bea 2180 in chronic obstructive pulmonary disease (COPD), sponsored by Boehringer Ingelheim. Started Jun 2004; status: completed.
02
Drugs
bea 2180
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02242279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02242279.